March 30 - April 2, 2020

FierceHealthcare and FiercePharma Present:
Coronavirus Virtual Series

Free Virtual Event


FiercePharma and FierceHealthcare bring you a week of virtual updates and expert panels discussing the coronavirus. We’ll assemble a series of experts to discuss industry’s role in preparing for a pandemic and what steps can be taken to mitigate risk while dealing with the outbreak.

Coverage areas include vaccine development, supply chain disruptions, diagnostic advances, payer’s role in containment, physician/provider preparedness, and technology’s role in preventing and treating outbreaks.


Monday, March 30

Now Available On-Demand | 11:00am-12:00pm ET | Physician/provider preparedness: How to prepare for a coronavirus outbreak within your facility
Now Available On-Demand 1:00pm-1:30pm ET | COVID-19: Six things health organizations should consider (but may not be)
Now Available On-Demand 3:00pm-4:00pm ET | The race to develop a vaccine for COVID-19

Tuesday, March 31

Now Available On-Demand 11:00am-12:00pm ET | How tech will help U.S. healthcare fight coronavirus
Now Available On-Demand 1:00pm-2:00pm ET | Crisis Consumer Outreach: Coronavirus and Beyond 
Now Available On-Demand 3:00pm-4:00pm ET | Challenge accepted: Biopharma puts COVID-19 in its pipeline

Wednesday, April 1

Now Available On-Demand 11:00am-12:00pm ET | The critical role of payers in stopping the spread of coronavirus
Now Available On-Demand 1:00pm-1:30pm ET |
 Solutions for rapid development and manufacturing responses to public health threats
Now Available On-Demand 3:00pm-4:00pm ET | COVID-19 threatens pharma’s global supply chain. What next?

Thursday, April 2

Now Available On-Demand 1:00pm-2:00pm ET | Cutting-edge approaches to support clinical development and evidence generation in the COVID-19 era

These virtual events are free! Click here to register now.


Physician/provider preparedness: How to prepare for a coronavirus outbreak within your facility
Recorded on: March 30, 2020 | 11:00AM-12:00PM ET

Coronavirus is clearly spreading in the U.S. now and providers are on the front lines of responding. How well are facilities preparing? What should they be doing to ramp up for large numbers of patients? What solutions should they be considering for handling the influx, including the supply chain, workforce concerns, revenue impacts during potential outbreaks? Our experts take a look at the current situation and offer their insights into what providers should be considering and be proactive in their response to COVID-19.


Gregg Miller, M.D.

Chief Medical Officer
Vituity Healthcare

Alan Kumar, M.D.

Emergency Medicine Physician
Community Hospital in Munster, IN

Laura Seng

Chairwoman of National Healthcare Department
Barnes & Thornburg

Tina Reed

Executive Editor

Linda Ruschau

Chief Client Officer

COVID-19: Six things health organizations should be considering (but might not be)

Recorded on: March 30, 2020 | Time: 1:00PM-1:30PM ET

The US healthcare system could potentially be tested as a pandemic broadens, flooding its emergency rooms, intensive care units, physician offices, urgent care clinics and telehealth lines with patients suffering from the symptoms of COVID-19. Leveraging insights from PwC Health Research Institute's latest report, COVID-19: Six things health organizations should consider (but might not be), a panel of PwC health experts will examine key considerations for healthcare organizations as they make and execute their short- and long-term plans for handling the pandemic. 

Presented by:


Igor Belokrinitsky

Health Services, PwC

James McNeil

Health Services, PwC

Vitaly Glozman

Pharma and Life Sciences, PwC

Benjamin Isgur

PwC's Health Research Institute Leader

Sarah Haflett

Sarah 100x100 PwC.jpg

Director, Health Research Institute 

The race to develop a vaccine for COVID-19
Recorded on: March 30, 2020 | Time: 3:00PM-4:00PM ET

In under three months, the novel coronavirus has spread to more than 100 countries, causing nearly 200,000 illnesses and thousands of deaths. The pandemic has created an urgent need for vaccines, and the scientific community is responding. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are pooling resources to aid vaccine development, with one candidate already in early human tests. In this virtual roundtable, experts will discuss vaccine approaches in the works, plus challenges to development, potential timing of a deployable vaccine and more.


Shlomi Madar, Ph.D

VP Healthcare Solutions
Signals Analytics

Michael Breen


Associate Director of Infectious Diseases

Kizzmekia S. Corbett PhD


Research Fellow
NIH, NIAID, Vaccine Research Center

Jim Mayne, Ph.D.

Vice President, Science and Regulatory Advocacy

Eric von Hofe

Chief Scientific Officer
NuGenerex Immuno-Oncology (NGIO)

Catherine Calarco

Sr Director & Global Industry Lead – Life Sciences
Automation Anywhere

Eric Sagonowsky


How tech will help U.S. healthcare fight coronavirus
Recorded on: March 31, 2020 | 11:00AM-12:00PM ET

Technology has quickly emerged as one of the early potential heroes in the fight against the novel coronavirus. Specifically, telehealth platforms have emerged as an option to divert traffic from emergency departments, conduct screening and in-home monitoring, maximize resources, limit clinician exposure to infected patients and engage patients around protecting themselves. Meanwhile, AI, wearables/remote monitoring and analytics technologies are helping to monitor patients and helping researchers to learn more about the disease. 

We will examine tech’s role in containing the spread of COVID-19 and examine both business opportunities and potential headwinds caused by the virus.


Peter Antall, M.D.

Chief Medical Officer

Linda Branagan, Ph.D.

Director of Telehealth Programs
University of California San Francisco Medical Center

Kuldeep Singh Rajput

CEO and Founder

Ann Mond Johnson

American Telemedicine Association

Heather Landi

Senior Editor

Linda Ruschau

Chief Client Officer

Crisis Consumer Outreach: Coronavirus and Beyond

Recorded on: March 31, 2020 | 1:00PM-2:00PM ET

Coronavirus (COVID-19) is top of mind throughout the United States and around the world. With rampant uncertainty, a rapid response with timely and relevant outreach can help inform consumers and safeguard their health. This roundtable will feature HMS’ Chief Medical Officer Dr. Gary Call, who has extensive experience working with Managed Care organizations, and will highlight the impact of this public health crisis as well as key considerations you can use to care for your various populations. Joining him are key members of HMS’ consumer engagement team, including Ellen Harrison, who will offer real-world strategies for incorporating crisis management into your communication plans through innovative messaging and digital technologies.


Presented by:


Gary Call, MD


Senior Vice President and Chief Medical Officer

Ellen Harrison, RN

VP of Population Health, Operations and Market Strategy

Challenge accepted: Biopharma puts COVID-19 in its pipeline
Recorded on: March 31, 2020 | 3:00PM-4:00PM ET

Numerous players are pitching into the fight against COVID-19, with pharma and biotech companies, governments, academic institutions, nonprofits and others working on tests to diagnose the disease and developing vaccines to prevent it. The third piece of the puzzle, is of course, treating infection. Here, experts will discuss therapeutics in the works, whether repurposed old drugs or brand new ones. They’ll address the challenges to their development and deployment, and sketch out typical timelines for the types of therapies in testing, or near it. The panel will also cover how outbreak response has evolved over the years, highlight lessons from previous outbreaks, and consider what is different about this one.


Amirah Al Idrus



George Scangos

Vir Biotechnology

Zhi Hong, Ph.D.

Co-founder, President, and Chief Executive Officer
Brii Biosciences

Amanda Bosse

President, Drug Product Division North America Pharma Services
Thermo Fisher Scientific

Ann Leen, Ph.D.

Co-Founder and Chief Scientific Officer

The critical role of payers in stopping the spread of coronavirus
Recorded on: April 1, 2020 | 11:00AM-12:00PM ET

As COVID-19 begins to spread in the U.S., health plans will take on a crucial role in prevention and education, in addition to
developing new payment approaches to covering new vaccines or therapies. Payers have a direct line to their members and can be a critical partner for providers in both educating people and preventing the spread of false information.


Kate Barry

Senior Vice President of Clinical Affairs and Strategic Partnerships
America's Health Insurance Plans (AHIP)

Beth Leonard

Chief Marketing and Communications Officer
EmblemHealth Family of Companies

Vincent Nelson, M.D.

VP, Medical Affairs and Interim Chief Medical Officer
Blue Cross Blue Shield Association (BCBSA)

Paige Minemyer

Senior Editor

Solutions for rapid development and manufacturing responses to public health threats

Recorded on: April 1, 2020 | 1:00PM-1:30PM ET

Mounting a rapid and effective response to emerging public health threats is a continuing challenge, which will only become more important in an increasingly connected world.  Critical to these responses is the ability to rapidly develop, scale and manufacture novel vaccines and therapeutics.  Emergent will present how we have leveraged our development and manufacturing network and close relationships to support innovators in producing vaccines and therapeutics to respond to these challenges.  Specific topics related to effective response to emerging public health threats include:

  • Automation and innovation: speeding development data to support clinical trial material manufacturing
  • Technology transfer: developing a flexible approach to decrease risk and time to production
  • Flexible facilities: flexible development and GMP facilities to decrease time to clinic and improve ability to support platform-based approaches
  • Case studies on responses to prior outbreaks

Presented by:



Rick Welch

Vice President, Head of Development Services, CDMO
Emergent BioSolutions

COVID-19 threatens pharma’s global supply chain. What next?
Recorded on: April 1, 2020 | 3:00PM-4:00PM ET

In an increasingly global pharmaceutical supply chain, the COVID-19 outbreak has posed an existential challenge to an industry working across national borders. The virus has already shut down some production in China and affected exports of some active pharmaceutical ingredients from India. With access strained, cost inevitably increases. 

A few key questions: How much of that cost can be passed along and how much must producers assume? Should the industry rewrite its supply chain script going forward? What policies should regulators have in hand to protect drug supplies for patients? Is it time for governments to subsidize API production in their own countries to insure constant supplies or can the market sort this out? In this roundtable, experts will discuss the current challenges COVID-19 presents to the global supply chain and what improvements Big Pharma and biotech firms should make from the outbreak moving forward.


Chris Chen

WuXi Biologics

Damien Holly

Head, Supply Chain

Leon Wyszkowski

President, Commercial Operations
Thermo Fisher Scientific

Kyle Blankenship


Cutting-edge approaches to support clinical development and evidence generation in the COVID-19 era
Recorded on: April 2, 2020 | 1:00PM-2:00PM ET

COVID-19 is threatening the conduct and completion of clinical studies, including real-world evidence (RWE) generation studies and randomized clinical trials (RCTs). This creates a pressing need for innovative and flexible approaches to the collection and analyses of study data. This virtual session addresses two specific areas that can have a substantial impact. The first discusses decentralizing the collection of real-world data with the integration of virtual and digital enablement into development and execution strategies. The second addresses the use of simulation to overcome difficulties in completing studies or even randomizing sufficient patients. This novel approach provides a means to make detailed predictions of what would have happened to enrolled patients assigned to the control arms had they completed the study, or even to dispense with a comparator arm altogether to focus on the experimental treatment.

Presented by:



Jaime Caro

Chief Scientist

Mariah Baltezegar, MBA

Executive Director, Head of Peri- and Post-Approval Virtual Trials

Rebecca Willumson

Vice President & Publisher
FierceLife Sciences and FierceHealthcare